Castration Levels of Testosterone clinical trials at UC Cancer
1 research study open to eligible people
ATR Kinase Inhibitor M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
open to eligible males ages 18 years and up
This phase II trial studies how well ATR kinase inhibitor M6620 and carboplatin with or without docetaxel works in treating patients with castration-resistant prostate cancer that has spread to other places in the body. ATR kinase inhibitor M6620 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ATR kinase inhibitor M6620, carboplatin and docetaxel may work better in treating patients with metastatic castration-resistant prostate cancer.
at UC Davis